We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+11.42%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.24%
AUM
$11.6B
AUM Growth
+$243M
(+2.1%)
Cap. Flow
-$770M
Cap. Flow
% of AUM
-6.61%
Top 10 Holdings %
Top 10 Hldgs %
17.24%
Holding
303
New
50
Increased
66
Reduced
133
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$102M |
| 2 |
S&P Global
SPGI
|
+$82.9M |
| 3 |
Intercontinental Exchange
ICE
|
+$72.4M |
| 4 |
Nike
NKE
|
+$55.5M |
| 5 |
Avery Dennison
AVY
|
+$49.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$95.4M |
| 2 |
TJX Companies
TJX
|
+$94.8M |
| 3 |
Chubb
CB
|
+$87.2M |
| 4 |
Intel
INTC
|
+$80.1M |
| 5 |
Union Pacific
UNP
|
+$73.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.27% |
| 2 | Technology | 17.63% |
| 3 | Consumer Discretionary | 13.42% |
| 4 | Industrials | 12.91% |
| 5 | Communication Services | 12.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
126
DELISTED
Acceleron Pharma
XLRN
| $30.4M | 0.26% |
1,147,919
-104,490
| -8% | -$2.75M |
|
|
BHI
127
DELISTED
Baker Hughes
BHI
| $29.9M | 0.26% |
499,210
-461,622
| -48% | -$28.1M |
|
|
ZEN
128
DELISTED
ZENDESK INC
ZEN
| $28.9M | 0.25% |
1,031,640
-148,995
| -13% | -$3.86M |
|
|
KATE
129
DELISTED
Kate Spade & Company
KATE
| $28.9M | 0.25% |
+1,243,450
| New | +$26M |
|
130
Caesars Entertainment
CZR
$6.06B
| $28.8M | 0.25% |
1,521,901
+286,205
| +23% | +$4.82M |
|
131
Integra LifeSciences
IART
$1.41B
| $28.8M | 0.25% |
683,625
-12,667
| -2% | -$541K |
|
132
O'Reilly Automotive
ORLY
$73.5B
| $28.4M | 0.24% |
1,578,840
-60,420
| -4% | -$1.09M |
|
|
WNR
133
DELISTED
Western Refining Inc
WNR
| $28.3M | 0.24% |
806,620
+87,730
| +12% | +$3.17M |
|
134
Essent Group
ESNT
$6.19B
| $27.6M | 0.24% |
+762,310
| New | +$26.5M |
|
135
Madison Square Garden
MSGS
$9.54B
| $27.6M | 0.24% |
193,553
-26,841
| -12% | -$3.49M |
|
136
Dana Inc
DAN
$2.94B
| $27.6M | 0.24% |
+1,427,106
| New | +$27.7M |
|
137
Liberty Broadband Class A
LBRDA
$4.91B
| $27.2M | 0.23% |
319,885
-63,660
| -17% | -$5.22M |
|
138
Vulcan Materials
VMC
$35.9B
| $27.2M | 0.23% |
225,770
+19,220
| +9% | +$2.35M |
|
139
Monolithic Power Systems
MPWR
$65.3B
| $26.9M | 0.23% |
292,031
-63,246
| -18% | -$5.6M |
|
|
INXN
140
DELISTED
Interxion Holding N.V.
INXN
| $26.8M | 0.23% |
678,085
-6,615
| -1% | -$254K |
|
141
Brunswick
BC
$5.21B
| $26.6M | 0.23% |
434,226
+56,505
| +15% | +$3.34M |
|
142
Hexcel
HXL
$7.67B
| $26M | 0.22% |
477,010
+65,094
| +16% | +$3.42M |
|
|
PFPT
143
DELISTED
Proofpoint, Inc.
PFPT
| $25.4M | 0.22% |
341,034
+107,455
| +46% | +$8.54M |
|
|
BID
144
DELISTED
Sotheby's
BID
| $24.3M | 0.21% |
534,965
+106,380
| +25% | +$4.55M |
|
145
Fidelity National Information Services
FIS
$23.6B
| $24M | 0.21% |
+301,640
| New | +$24.3M |
|
|
CLVS
146
DELISTED
Clovis Oncology, Inc.
CLVS
| $23.9M | 0.21% |
375,530
-53,655
| -13% | -$3.26M |
|
|
ORBK
147
DELISTED
Orbotech Ltd
ORBK
| $23.9M | 0.21% |
741,042
+135,565
| +22% | +$4.38M |
|
|
RP
148
DELISTED
RealPage, Inc.
RP
| $23.9M | 0.2% |
683,878
-127,105
| -16% | -$4.15M |
|
|
BMCH
149
DELISTED
BMC Stock Holdings, Inc
BMCH
| $23.6M | 0.2% |
+1,045,550
| New | +$21.2M |
|
|
UNVR
150
DELISTED
Univar Solutions Inc.
UNVR
| $23.4M | 0.2% |
762,059
-1,131
| -0.1% | -$34K |
|
Similar funds
OAG
JG
CHP
SAM
Westfield Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, Westfield Capital Management held 303 positions worth $11.6B, up 2.1% from $11.4B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Westfield Capital Management withdrew a net $770M in Q1 2017, closing 45 positions and reducing 133 holdings. Its most notable exit was TJX Companies, an estimated $94.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Westfield Capital Management opened a new position in Biogen worth $98.2M.
- Westfield Capital Management's largest Q1 2017 buy was Biogen: 359,107 shares worth $98.2M.
- Westfield Capital Management added most to Walt Disney in Q1 2017, an estimated $48.8M increase.
- Westfield Capital Management's biggest Q1 2017 reduction was Gilead Sciences, cutting an estimated $95.4M.
- Westfield Capital Management fully exited TJX Companies in Q1 2017, selling an estimated $94.8M.
- Westfield Capital Management's ten largest holdings make up 17% of its $11.6B portfolio in Q1 2017.
- Westfield Capital Management opened 50 new positions and closed 45 in Q1 2017.
- Westfield Capital Management's portfolio value rose 2.1% quarter-over-quarter to $11.6B.
Based on Westfield Capital Management's 13F filing for Q1 2017, filed 12 May 2017.